The startup develops anti-tumor monoclonal human recombinant antibodies that utilize antibody-drug conjugates to specifically target cancer cells and deliver cytotoxic agents directly into them. This approach enhances the precision of cancer treatment, minimizing damage to healthy tissues while maximizing therapeutic efficacy.
Funding
$110.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
TFounders
Product
Problem
Despite advancements in antibody-drug conjugate (ADC) therapies, the need for novel ADC targets remains, especially for cancers resistant to existing treatments or those lacking effective therapies. Traditional antibody selection methods often fail to translate from in vitro to in vivo settings due to the complexities of the tumor microenvironment.
Solution
MBrace Therapeutics is developing first-in-class ADC therapeutics by utilizing its proprietary SPARTA technology to identify novel cancer targets. The SPARTA platform employs in vivo screening to discover antibodies that selectively bind to cancer cells, internalize upon binding, and are accessible in the body. This approach enables the development of ADCs against previously intractable targets, increasing efficacy and reducing off-target toxicity. MBrace's lead ADC product, MBRC-101, is currently in Phase 1 clinical trials for advanced refractory solid tumors and targets EphA5, a transmembrane tyrosine kinase receptor highly expressed in various solid tumors.
Target Audience
The primary target audience includes cancer patients with advanced refractory solid tumors, as well as physicians and clinical researchers seeking new treatment options and novel therapeutic strategies.
Features
- SPARTA technology: In vivo antibody selection for improved target specificity and internalization
- Development of ADCs targeting novel antigens inaccessible to traditional methods
- MBRC-101: Lead ADC product targeting EphA5, currently in Phase 1 clinical trials
- Potential for reduced side effects compared to conventional chemotherapies due to highly targeted approach
- Proprietary approach to manufacturing antibodies against intracellular targets
- Discovery of therapeutic targets present across many cancer types